Lenalidomide enhances anti-myeloma cellular immunity-Reference-Cited by-同舟云学术

Lenalidomide enhances anti-myeloma cellular immunity

Published:2012-06-24 Issue:1 Volume:62 Page:39-49
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Luptakova Katarina,Rosenblatt Jacalyn,Glotzbecker Brett,Mills Heidi,Stroopinsky Dina,Kufe Turner,Vasir Baldev,Arnason Jon,Tzachanis Dimitri,Zwicker Jeffrey I.,Joyce Robin M.,Levine James D.,Anderson Kenneth C.,Kufe Donald,Avigan David

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-012-1308-3.pdf

Reference45 articles.

1. Pratt G, Goodyear O, Moss P (2007) Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 138:563–579

2. Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800

3. Rosenblatt J, Glotzbecker B, Mills H et al (2011) PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 34:409–418

4. Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123–2132

5. Weber DM, Chen C, Niesvizky R et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133–2142

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy;Trends in Molecular Medicine;2024-08

2. CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors;Med;2024-06

3. Treatment of multiple myeloma: What is the impact on T-cell function?;Therapeutic Advances in Hematology;2024-01

4. Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models;Theranostics;2024

5. Immune checkpoint inhibitors for multiple myeloma immunotherapy;Experimental Hematology & Oncology;2023-11-28